Emerging antiviral drugs for hepatitis C virus

Reviews on Recent Clinical Trials

Volumn 4, Issue 3, 2009, Pages 179-184

  Enomoto, Masaru ^a   Tamori, Akihiro ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus; Interferon; Polymerase inhibitor; Protease inhibitor; Ribavirin; STAT C

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANA 598; ANTIVIRUS AGENT; BOCEPREVIR; C 201; CILUPREVIR; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; ERYTHROPOIETIN; FILIBUVIR; GS 9190; ITMN 191; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PF 00868554; PROTEINASE INHIBITOR; R 7128; RIBAVIRIN; RIBAVIRIN DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TARIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; CODON; CROSS RESISTANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; NAUSEA; NONHUMAN; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS;

EID: 73349125127     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709789957628     Document Type: Review

References (39)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
5. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
6. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-33.
7. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436: 930-2.
8. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-87.
9. Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48: 313-20.
10. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
11. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-9.
12. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671-8.
13. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 407-17.
14. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
15. Davis GL, Esteban-Mur R, Rustgi V, et al. International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
16. McHutchison JG, Manns MP, Brown RS, Jr., Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9.
17. Gish RG, Arora S, Rajender RK, et al. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007; 47: 51-9.
18. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
19. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-8.
20. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
21. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
22. Manns M, Muir A, Adda N, et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study. J Hepatol 2009; 50 (Suppl 1): S379.
23. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-8.
24. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegIntron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C. J Hepatol 2009; 50(Suppl 1): S4.
25. Manns M, Reesink H, Moreno C, et al. Opera-1 Trial: Interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype 1 HCV patients. J Hepatol 2009; 50(Suppl 1): S7. [26] Forestier N, Larrey DG, Guyader D, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a rhase 1b multiple ascending dose (MAD) study. Hepatology 2008; 48(Suppl): 1132A.
26. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48: 85-97. [28] Pockros P, Nelson D, Godofsky E, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 2008; 48: 1349-50.
27. Rodriguez-Torres M, Lalezari J, Gane EJ, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-IFN and ribavirin: subanalysis by race/ethnicity, weight and HCV genotype. Hepatology 2008; 48(Suppl): 1160A.
28. Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days. Hepatology 2008; 48(Suppl): 1024A.
29. Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment-naïve patients chronically infected with HCV genotype 1. J Hepatol 2009; 50(Suppl 1): S382-3.
30. Bavisotto L, Wang CC, Jacobson IM, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5b polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology 2007; 46(Suppl): 255A.
31. Lawitz E, Rodriguez-Torres M, DeMico M, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 2009; 50(Suppl 1): S384.
32. Nettles R, Chien C, Chung E, et al. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 2008; 48(Suppl): 1025A.
33. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136: 856-62.
34. Elazar M, Liu M, McKenna SA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of elongation initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009 (in press).
35. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-41.
36. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43: 761-70.
37. Inoue K, Umehara T, Ruegg UT, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007; 45: 921-8.
38. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009; 49: 1460-8.
39. Gane EJ, Roberts SK, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase inhibitor (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics and virologic results from INFORM-1. J Hepatol 2009; 50(Suppl 1): S380.